.jpg)
Johnson & Johnson agrees to pay $230 million to settle opioid case in New York
On the eve of a widely anticipated trial, Johnson & Johnson (JNJ) has agreed to…
Category: Pharmalot
STAT+: In an about-face, Health Canada allows a controversial rare disease drug back on the market
In yet another twist in a complicated tale, Health Canada has reinstated approval of a…
STAT+: Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows
The pharmaceutical industry has developed a “hidden web of policy influence” over members of the…
STAT+: As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat rare infection
Over the past few months, thousands of people in India who survived Covid-19 returned to…
STAT+: Pharmalittle: Sanofi dengue vax endorsed by expert CDC panel; Pfizer recalls Chantix as it tests for possible carcinogens
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s drugs?
In an unexpected move, U.S regulators granted Eli Lilly (LLY) a breakthrough designation for its…
STAT+: Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens
After finding potential carcinogens in some lots of Chantix, Pfizer (PFE) late last month halted…
STAT+: Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism
Hello, everyone, and nice to see you again after a day off. We can explain…
STAT+: Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup
Good morning! Elizabeth Cooney here, sitting in for Ed Silverman, who would no doubt be…
STAT+: Teva to pay $925,000 to Mississippi to settle generic price-fixing charges
After years of controversy, Teva Pharmaceuticals (TEVA) agreed to pay $925,000 to the state of…
STAT+: Pharmalittle: Biogen isn’t the only company to make big bucks from its Alzheimer’s drug; EU extends Covid-19 vax export block
Hello, everyone, and how are you this morning? Some puffy clouds are hovering over the…
STAT+: Cost-effectiveness studies for widely used Medicare Part D drugs are few and far between
As more emphasis is placed on the value of prescription medicines, a new study found…
STAT+: HHS withdraws 340B drug discount opinion amid lawsuits by pharma companies
After a defeat in federal court, the Department of Health and Human Services withdrew an…
STAT+: Pharmalittle: Glaxo CEO under fire ahead of investor meeting; CureVac not giving up on its Covid-19 vaccine
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Medical journal argues a drug maker’s libel suit is really a public relations campaign to chill research
File this under “Not every legal brief is eye-glazing.” Two months ago, Pacira Biosciences (PCRX)…
STAT+: European Union loses bid for faster deliveries of AstraZeneca Covid-19 vaccine
The European Union failed in its attempt to force AstraZeneca (AZN) to speed deliveries of…
STAT+: A California law that bans drug coupons failed to increase generic use
A California law that banned coupons for brand-name prescription drugs failed to significantly boost greater…
STAT+: Pharmalittle: Biden to spend $3 billion to develop Covid-19 pills; most Americans believe the new Alzheimer’s drug will be effective
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Poll: Many Americans concerned about FDA approval process for Alzheimer’s drug
Two-thirds of Americans who are familiar with the details of the newly approved Alzheimer’s treatment…
STAT+: Billions spent on prescription drug ads may have increased Medicare spending
The large sums of money spent on advertising prescription drugs directly to consumers may have…
STAT+: Pharmalittle: CureVac Covid-19 shot was 47% effective in a trial; pricey brain cancer drug no longer covered by Medicare
Rise and shine, everyone, another busy day is on the way. Even so, there is…
STAT+: Planned changes at Soros’ Open Society has access-to-medicines advocacy groups on edge
The Open Society Foundations, one of the world’s largest backers of public health initiatives, is…
STAT+: American Medical Association delegates vote to support controversial Covid-19 IP waiver
The American Medical Association delegates voted at their annual meeting to support a controversial proposal…
STAT+: Pharmalittle: Regeneron Covid-19 drug cuts risk of death in some patients; bills reintroduced to help develop new antibiotics
Good morning, folks. And how are you today? We are in fine spirits, thanks to…
STAT+: Lawmakers revive legislation to accelerate the development of new antibiotics
After months of anticipation, a bipartisan group of U.S. lawmakers is reintroducing bills in the…
STAT+: ‘A litany of flaws’: Advocacy group urges HHS to boot FDA officials over Alzheimer’s drug approval
Reacting to the controversial approval of the Biogen (BIIB) Alzheimer’s drug, a leading advocacy group…
STAT+: Centene to pay $143 million to two states to settle allegations of overcharging Medicaid
Centene (CNC), a major health insurer, agreed to pay a combined $143 million to Ohio…
STAT+: Pharmalittle: AstraZeneca antibody therapy failed to prevent Covid-19; former FDA Commish Hahn joins Moderna backer
Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy…
STAT+: Mississippi becomes the first state to jointly sue drug makers and PBMs over the cost of insulin
In a first-of-its-kind move, the Mississippi attorney general last week filed a lawsuit accusing several…
STAT+: Pharmalittle: Novavax says Covid-19 shot is highly effective; doctors scramble to advise patients on Alzheimer’s drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine
In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag…
STAT+: Pharmalittle: A third FDA panel member resigns over Alzheimer’s drug approval; agency’s decision hardens opposition to Woodcock
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: U.S. to donate 500 million Covid vaccine doses; WTO to step up talks on waiving IP protection for Covid shots
Good morning and congrats if you caught the “ring of fire” some of us in…
STAT+: WTO members agree to step up talks about Covid-19 intellectual property proposals
In what is being described as a “major breakthrough,” a World Trade Organization council agreed…
STAT+: Pharmalittle: Biogen and FDA at odds over a key Alzheimer’s drug trial; Senate Dems craft their own drug-pricing bill
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT+: Regeneron shareholders urged to boot board member over executive pay practices
Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove the board…
STAT+: Pharmalittle: FDA rewrites rulebook in approving Alzheimer’s drug; Biogen’s price for the drug will strain Medicare
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: ‘The price is bewildering’:The price of Biogen’s Alzheimer’s drug may lead payers to erect roadblocks
The Food and Drug Administration’s approval on Monday of an Alzheimer’s drug developed by Biogen…
STAT+: Pharmalittle: AstraZeneca sues Glaxo over a big-selling cancer drug; EU offers rival plan to Covid-19 IP waiver
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: EU pushes rival plan to Covid-19 vaccine IP waiver, but some deride it as ‘meaningless’
Amid intense debate over equitable access to Covid-19 vaccines, the European Union is offering a…
STAT+: Pharmalittle: A turnaround artist hopes to revamp a former Shkreli company; will the FDA approve Biogen’s Alzheimer’s drug?
And so, another working week will soon draw to a close. Not a moment too…
STAT+: After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug…
STAT+: Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval
A lymphoma drug that was approved later than expected by regulators is at the center…
STAT+: Pharmalittle: Purdue bankruptcy plan clears a major hurdle; Senate Finance chair probes AbbVie over taxes
Good morning, everyone, and how are you today? A spot of rain, and then some,…
STAT+: Senate finance chair investigates AbbVie over its corporate tax strategy
AbbVie, which is already being probed by congressional Democrats for its pricing practices, is now…
STAT+: Industry payments to doctors are associated with increased prescribing of long-acting insulin
Amid ongoing concern over the cost of insulin, a new study finds that payments made…
STAT+: Pharmalittle: JAMA editor stepping down after podcast furor; global agencies urge $50 billion investment to fight Covid-19
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: FTC issues a non-committal report on ‘rebate walls,’ but will the agency dig deeper?
In response to Congressional concerns over prescription drug pricing, the Federal Trade Commission released a…
‘A perilous point’: Global agencies call for $50 billion investment to combat Covid-19
In a plea to halt the Covid-19 pandemic, four global agencies are calling for investments…
STAT+: Pharmalittle: Biden in no rush to allow drug imports from Canada; deal on Covid-19 IP waiver remains elusive
Hello, everyone, and nice to see you again after taking an extended weekend break. Nothing…